Cancer Microenvironment and Cancer Vaccine

Overview

Journal Cancer Microenviron

Publisher Springer

Specialty Oncology

Date 2012 May 8

PMID 22562695

Citations 7

Authors

Zhen-Yu Ding

Xue-Lin Zou

Yu-quan Wei

Affiliations

Soon will be listed here.

Abstract

The cancer microenvironment is constituted of non-transformed host stromal cells such as endothelial cells, fibroblasts, various immune cells, and a complex extra-cellular matrix secreted by both the normal and neoplastic cells embedded in it. The importance of the microenvironment and its potential in cancer therapy is just being established. Among modalities that target the microenvironment, cancer vaccine is a unique strategy which is aimed to elicit specific immunity against components in the microenvironment. Most, if not all, components can be targeted by the vaccines. The most extensively studied are the endothelial cells, fibroblasts and macrophages as well as ECM. Vaccines are in development for each of them. All the vaccines were proved to be effective at providing protective or therapeutic anti-tumor effects in the pre-clinical models. A few of them have been tested in the clinical trials. The mechanisms of the vaccines were mainly related to the cellular immune response such as CD8+ cytotoxic T cells, and in some instances CD4+ Th cells were involved as well. The present review also discussed the hurdles associated with the microenvironment-based vaccines such as the selection of suitable patients with appropriate biomarkers. With the rapid increase of our knowledge in the cancer microenvironment, the proof-of-concept of microenvironment-based cancer vaccines will surely expand our armamentarium against cancer.

Citing Articles

FSTL1 Suppresses Triple-Negative Breast Cancer Lung Metastasis by Inhibiting M2-like Tumor-Associated Macrophage Recruitment toward the Lungs.

Yang Y, Lu T, Jia X, Gao Y Diagnostics (Basel). 2023; 13(10).

PMID: 37238210 PMC: 10217361. DOI: 10.3390/diagnostics13101724.

Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines.

Lokhov P, Balashova E, Trifonova O, Maslov D, Archakov A Pharmaceutics. 2023; 15(2).

PMID: 36839983 PMC: 9963030. DOI: 10.3390/pharmaceutics15020661.

Sweat Gland Tumor Microenvironment.

Handaya A, Anwar S, Fauzi A, Werdana V Adv Exp Med Biol. 2021; 1296:259-274.

PMID: 34185298 DOI: 10.1007/978-3-030-59038-3_16.

Pyruvate Kinase M2: a Metabolic Bug in Re-Wiring the Tumor Microenvironment.

Rihan M, Nalla L, Dharavath A, Shard A, Kalia K, Khairnar A Cancer Microenviron. 2019; 12(2-3):149-167.

PMID: 31183810 PMC: 6937361. DOI: 10.1007/s12307-019-00226-0.

T cells in tumor microenvironment.

Kiraz Y, Baran Y, Nalbant A Tumour Biol. 2015; 37(1):39-45.

PMID: 26476540 DOI: 10.1007/s13277-015-4241-1.

References

Scapini P, Morini M, Tecchio C, Minghelli S, Di Carlo E, Tanghetti E . CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol. 2004; 172(8):5034-40. DOI: 10.4049/jimmunol.172.8.5034. View

Liu J, Wei Y, Yang L, Zhao X, Tian L, Hou J . Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood. 2003; 102(5):1815-23. DOI: 10.1182/blood-2002-12-3772. View

Aikawa T, Gunn J, Spong S, Klaus S, Korc M . Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther. 2006; 5(5):1108-16. DOI: 10.1158/1535-7163.MCT-05-0516. View

Wei Y, Wang Q, Zhao X, Yang L, Tian L, Lu Y . Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med. 2000; 6(10):1160-6. DOI: 10.1038/80506. View

Cheng J, Dunbrack Jr R, Valianou M, Rogatko A, Alpaugh R, Weiner L . Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 2002; 62(16):4767-72. View

Liotta L, Kohn E . The microenvironment of the tumour-host interface. Nature. 2001; 411(6835):375-9. DOI: 10.1038/35077241. View

Kaplan C, Kruger J, Zhou H, Luo Y, Xiang R, Reisfeld R . A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. Vaccine. 2006; 24(47-48):6994-7002. DOI: 10.1016/j.vaccine.2006.04.071. View

Rosenberg S, Yang J, Restifo N . Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004; 10(9):909-15. PMC: 1435696. DOI: 10.1038/nm1100. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

10.

Liotta L, Tryggvason K, Garbisa S, Hart I, FOLTZ C, Shafie S . Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980; 284(5751):67-8. DOI: 10.1038/284067a0. View

11.

He Q, Wei Y, Tian L, Zhao X, Su J, Yang L . Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem. 2003; 278(24):21831-6. DOI: 10.1074/jbc.M300880200. View

12.

Heid H, Moll R, Schwetlick I, Rackwitz H, Keenan T . Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res. 1998; 294(2):309-21. DOI: 10.1007/s004410051181. View

13.

Mitchell M, Abrams J, Thompson J, Kashani-Sabet M, DeConti R, Hwu W . Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol. 2007; 25(15):2078-85. DOI: 10.1200/JCO.2006.10.1709. View

14.

Kessenbrock K, Plaks V, Werb Z . Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67. PMC: 2862057. DOI: 10.1016/j.cell.2010.03.015. View

15.

Niethammer A, Xiang R, Becker J, Wodrich H, Pertl U, Karsten G . A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002; 8(12):1369-75. DOI: 10.1038/nm1202-794. View

16.

de Wever O, Nguyen Q, Van Hoorde L, Bracke M, Bruyneel E, Gespach C . Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J. 2004; 18(9):1016-8. DOI: 10.1096/fj.03-1110fje. View

17.

Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L . Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J. 2002; 16(2):267-9. DOI: 10.1096/fj.01-0651fje. View

18.

Fidler I . The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3(6):453-8. DOI: 10.1038/nrc1098. View

19.

Rosenberg S, Restifo N, Yang J, Morgan R, Dudley M . Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8(4):299-308. PMC: 2553205. DOI: 10.1038/nrc2355. View

20.

Cheng W, Chang M, Sun W, Lee C, Lin H, Su Y . Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism. Gene Ther. 2008; 15(13):1007-16. DOI: 10.1038/gt.2008.25. View